Development of diagnostics for COVID-19 has followed an accelerated timeline

- **31 Dec 2019:** Cluster of "pneumonia of unknown cause" identified in Wuhan
- **12 Jan:** WHO first teleconference with Dx and lab network
- **20 Jan:** WHO screened manufacturers to produce requested kits
- **13 Jan:** WHO first protocol for PCR assay released
- **29 Jan:** Production for requested kits started
- **28 Feb:** WHO Emergency Use Listing (EUL) procedure for PCR assays launched
- **15 Apr:** First purchase orders under the Dx Consortium issued
- **11 Jan:** Genetic sequencing shared
- **13 Jan:** WHO first protocol for PCR assay released
- **29 Jan:** Production for requested kits started
- **2 Feb:** First dispatch of PCR Dx kits to Regional and Country Offices
- **3 Mar:** Dx Consortium for COVID-19 established
- **24 Apr:** COVID-19 ACT Accelerator launched

To date: **37.4 million tests procured** across partners (Global Fund, GDF/StopTB, PAHO, UNDP, Unicef, WHO) with **over 27.1 million in transit or delivered**
Antigen RDT use recommended where PCR is unavailable or where prolonged turnaround times of PCR preclude clinical utility

| 1 | Respond to suspected outbreaks in remote settings, institutions and semi closed communities |
| 2 | Support outbreak investigations, helping to screen at-risk individuals and rapidly isolate positive cases |
| 3 | Monitor trends in disease incidence in communities, particularly for essential workers and healthcare workers |
| 4 | Where there is widespread community transmission, RDTs may be used for early detection and isolation, including asymptomatic contacts of cases |

Initial price for RDTs is expected to be a ceiling price of 5 USD decreasing in 2021 to 2-3 USD

- Planning to procure and ship 20 million RDTs/month
- Access and Allocation framework has been developed (incorporates epidemiological and vulnerability factors)
- Diagnostic tests have been delivered to 134 countries to date

Any questions regarding Diagnostics procurement or supply chain, please reach out to our email: COVID19Enquiry-Diagnostics@who.int.

**Dx Consortium**

<table>
<thead>
<tr>
<th>Resource location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Access and Allocation FAQs</td>
</tr>
<tr>
<td>EUL listed products:</td>
</tr>
</tbody>
</table>